Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2012	Dec. 31, 2011
Assets
Cash and cash equivalents	$ 17,373,866	$ 9,748,491
Prepaid research and development	1,719,828	0
Other current assets	64,652	87,176
Total current assets	19,158,346	9,835,667
Equipment, net	1,281	0
In-process research and development	5,441,839	5,441,839
Goodwill	629,752	629,752
Total assets	25,231,218	15,907,258
Liabilities and equity
Notes payable, current portion	677,778	877,778
Accounts payable - related party	1,799,424	0
Other accounts payable and accrued expenses	372,747	666,640
Interest payable, current portion	107,569	61,941
Total current liabilities	2,957,518	1,606,359
Notes payable, noncurrent portion, at fair value	4,380,400	4,664,697
Total liabilities	7,337,918	6,271,056
Commitments and contingencies
Equity:
Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 0 and 413,388 issued and outstanding as of September 30, 2012 and December 31, 2011, respectively, aggregate liquidation value of $0 and $8,267,760 at September 30, 2012 and December 31, 2011, respectively)	0	413
Common stock, $0.001 par value per share (500,000,000 shares authorized, 20,058,995 and 5,061,399 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively)	20,059	5,061
Contingently issuable shares	6	6
Additional paid-in capital	24,817,526	10,472,115
Deficit accumulated in development stage	(15,466,056)	(853,074)
Total TG Therapeutics, Inc. and subsidiaries equity	9,371,535	9,624,521
Noncontrolling interest in subsidiary	8,521,765	11,681
Total equity	17,893,300	9,636,202
Total liabilities and equity	$ 25,231,218	$ 15,907,258